Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir.
Juan A
JA
Pineda
Rosario
R
Palacios
Antonio
A
Rivero
Laila
L
Abdel-kader
Manuel
M
Márquez
Pilar
P
Cano
José A
JA
Mira
Julián
J
Torre-Cisneros
Fernando
F
Lozano
Jesús
J
Santos
D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D056486:Chemical and Drug Induced Liver Injury / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013030:Spain
D044966:Anti-Retroviral Agents; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate